Across TCGA pan-cancer cohorts, FADS3 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated FADS3 data layer compared with 28 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher FADS3 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated FADS3 expression acts as an unfavorable survival marker, although some lineages such as UCEC and LSCC show a favorable association.

PDAC, LUAD, and UCEC are the cancer types where FADS3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	II,III,IV	0.254	0.870	.010	19	view →
LUAD	DFS	Quartile	II,III,IV	0.151	0.748	.004	7	view →
UCEC	DFS	Tertile	All	1.000	0.846	.033	2	view →
LSCC	DFS	Median	II,III,IV	1.000	0.571	.030	2	view →
GBM	OS	Quartile	All	0.758	0.976	.048	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: FADS3 tumor-vs-normal RNA expression · all FADS3 data types